1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Opioids Overview to 2021 - An Assessment of Pain Management and Dependence

Opioids Overview to 2021 - An Assessment of Pain Management and Dependence

  • August 2015
  • 110 pages
  • ID: 3275008

Summary

Table of Contents

Opioids Overview to 2021 - An Assessment of Pain Management and Dependence

Summary

GBI Research’s latest report, "Opioids Overview to 2021 - An Assessment of Pain Management and Dependence" discusses the use of opioids as potent analgesics for the treatment of cancer and non-cancer pain and examines the management of opioid dependence in the US, the UK, Germany, Spain, Italy, France, Australia, Japan, India and China.

Analysis pertaining to the prescribed opioid users, treatment patterns, and market revenues confirms that the use of weak opioids has fallen dramatically in most markets, while the use of strong opioids has increased. The total market size in the countries covered in this report was $15.7 billion in 2014, of which the US accounted for the highest share, followed by Japan and Germany. The global prevalence of chronic pain was 20-30% in the same year, although most of the prevalence population received inadequate treatment due to the high potential for opioid abuse or misuse.

The report also discusses each country’s regulatory restrictions, as well as the treatments available for opioid dependence such as withdrawal management, maintenance, and psychosocial support. In addition, it examines dependence treatment settings, trends, and patient referral pathways. Patient access and cost of treatment remain the key barriers to effectively managing opioid dependence in most countries.

Scope

Dosage and treatment regimes for major opioids used in pain management -
- Which opioids are used for opioid-naïve patients and for patients that experience continuous pain but respond well to opioids?
- Which opioids are considered for first-line and second-line treatment?
Management of opioid dependence according to WHO treatment guidelines -
- What are the recommended medications for opioid maintenance, withdrawal, and overdose?
- What are the treatment regimes followed when using various pharmacotherapy drugs?
- What role does psychosocial treatment play?
In-depth country analysis of opioids for pain management, covering pain prevalence, level of opioid use, commonly used opioids, trends, barriers, and rationalization initiatives -
- What is the overall pain prevalence in each country and is it treated adequately?
- To what extent are opioids used to treat pain?
- What are the major opioids used and the key associated trends?
- Why are patients/prescribers often reluctant to use opioids for pain?
- What initiatives have been taken or recommended to facilitate appropriate use of opioids?
Regulatory landscape and guidelines for opioid prescription -
- Which regulatory laws and bodies oversee import, exports, schedules, and controls on opioids in each country?
- Which narcotic guidelines discuss the prescribing authorities and licenses required to possess or prescribe controlled drugs?
In-depth country analysis of treatment for opioid dependence in all countries, covering dependence, substance abuse trends, treatment usage patterns, and patient referral pathways -
- How many drug users receive treatment for opioid dependence?
- What are the medication usage trends in dependence treatment?
- What are the referral pathways for dependent patients?
Use of novel formulations to prevent abuse and address unmet need in pain management -
- How do agonist-antagonist, abuse-resistant, and overdose-reversal formulations aid abuse prevention?
Challenges addressing the unmet need in opioid dependence treatment -
- Which areas need to be improved to address the unmet need in opioid dependence treatment?

Reasons to buy

This report will allow you to -
- Identify users of prescribed opioids and associated revenues through 2021, as well as key pain management trends and the most frequently used opioids in the analyzed countries.
- Determine the drivers and restraints for opioid use in each country, examine patient/prescriber reasons for reluctance to use opioids for pain relief, and the initiatives being taken or recommended to facilitate appropriate use.
- Gain an understanding of the narcotic guidelines and regulations specific to each country, and determine the prescribing authorities and licenses required to posses/prescribe controlled drugs, the maximum length of time for which an opioid can be prescribed, and recent amendments.
- Analyze substance abuse and dependence trends, prescribing authorities, treatment usage patterns, and government funding for opioid dependence by examining the percentage of people receiving treatment for opioid misuse, the percentage of dependents receiving treatment, and usage trends associated with medications.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
2018 Global Drugs of Abuse Testing Market: US, Europe, Japan--Supplier Shares and Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

2018 Global Drugs of Abuse Testing Market: US, Europe, Japan--Supplier Shares and Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

  • $ 5500
  • Industry report
  • June 2018
  • by Venture Planning Group

This new 318-page report contains 68 tables and provides analysis of the global drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market ...

2018 Europe Drugs of Abuse Testing Market: France, Germany, Italy, Spain, UK--Supplier Shares and Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

2018 Europe Drugs of Abuse Testing Market: France, Germany, Italy, Spain, UK--Supplier Shares and Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

  • $ 4200
  • Industry report
  • June 2018
  • by Venture Planning Group

This new 300-page report provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic ...

Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025

Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025

  • $ 3499
  • Industry report
  • August 2018
  • by Roots Analysis Private Ltd.

INTRODUCTIONChronic pain refers to the psychophysiological response to an underlying clinical condition, which is observed to persist for a duration greater than six months and is generally unresponsive ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on